# Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

> **NCT02410863** · PHASE2 · TERMINATED · sponsor: **Prof. Dr. med. Dirk Schadendorf** · enrollment: 10 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02410863
- **Lead sponsor:** Prof. Dr. med. Dirk Schadendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** lack of recruitment due to changed therapy options
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410863, "Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02410863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*